SK Biopharmaceuticals Reports Q4 Operating Profit of 46.2 Billion Won, Up 13.8% – Driven by Strong Xcopri Sales (Comprehensive)
SK Biopharmaceuticals posted a 13.8% rise in Q4 operating profit to 46.2 billion won, driven by strong Xcopri sales and expanding its R&D pipeline for future growth.
SK Biopharmaceuticals Q3 Operating Profit Surges 262.4% on Robust Xcopri Sales (Comprehensive)
SK Biopharmaceuticals Co. reported a 262.4% year-on-year surge in Q3 operating profit, driven by robust Xcopri sales and cost efficiencies, far surpassing market expectations.
SK Biopharmaceuticals Posts Q3 Operating Profit of 70.1 Billion Won, Up 262.4%—Significantly Exceeds Forecasts (Update)
SK Biopharmaceuticals Co. reported a 262.4% surge in Q3 operating profit to 70.1 billion won, far surpassing market forecasts, driven by strong Xcopri sales and cost efficiencies.
'Cash Cow' Xcopri Drives SK Biopharmaceuticals—Q3 Operating Profit Expected to Surge 186%
SK Biopharmaceuticals is set to report a 186% surge in Q3 operating profit, driven by strong U.S. Xcopri sales and cost controls, though new product launches may temporarily lift expenses.
SK Biopharmaceuticals Co. delivered a surprise Q2 operating profit, driven by record US sales of its epilepsy drug Xcopri, with revenue and profit far exceeding market forecasts and strong momentum in both core and royalty streams.
#YonhapInfomax #SKBiopharmaceuticals #Xcopri #OperatingProfit #USSales #EpilepsyDrug #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=75569
SK Biopharmaceuticals Posts Surprise Q2 Operating Profit Surge—Driven by Xcopri Sales (Comprehensive Report 2)
SK Biopharmaceuticals Co. delivered a surprise Q2 operating profit, driven by record US sales of its epilepsy drug Xcopri, with revenue and profit far exceeding market forecasts and strong momentum in both core and royalty streams.
SK Biopharmaceuticals Posts Surprise Q2 Operating Profit Surge – Driven by Xcopri Sales (Comprehensive)
SK Biopharmaceuticals Co. delivered a surprise Q2 operating profit, driven by record US sales of epilepsy drug Xcopri, with revenue and profit far exceeding market forecasts.
SK Biopharm reports Q1 operating profit of 25.7 billion won, up 149% year-on-year, driven by U.S. sales growth of epilepsy drug Xcopri, despite lower-than-expected results and temporary factors affecting overall sales.
#YonhapInfomax #SKBiopharm #Q1Earnings #Xcopri #OperatingProfit #EpilepsyTreatment #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=62465SK Biopharm Q1 Operating Profit Up 149% to 25.7 Billion Won - 'Xcopri Sales on Track'
SK Biopharm reports Q1 operating profit of 25.7 billion won, up 149% year-on-year, driven by U.S. sales growth of epilepsy drug Xcopri, despite lower-than-expected results and temporary factors affecting overall sales.
SK Biopharm Forecasts 230% Increase in Q1 Operating Profit, Thanks to Xcopri
SK Biopharm forecasts 230% increase in Q1 operating profit, driven by strong Xcopri sales despite absence of milestone payments, as company navigates potential U.S. tariff challenges
Yonhap Infomax News